Do analysts prefer AVCT or FARN?

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 34.42%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Avacta Group is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate FARN or PRTC?

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 286.61%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is HZD or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Horizon Discovery Group plc (HZD.L) N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Which has better earnings and valuation, VRP or FARN?

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verona Pharma plc (VRP.L) N/A N/A N/A -£32.70 N/A Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A

Is VRP or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Verona Pharma plc (VRP.L) N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Do analysts rate FARN or BTG?

BTG has a consensus target price of GBX 160, indicating a potential upside of 33.33%. Given BTG's stronger consensus rating and higher possible upside, analysts plainly believe BTG is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is FARN or BTG more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% BTG N/A N/A N/A

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 42.15 -1.35 (-3.10%)

As of 06/19/2026 10:05 AM Eastern

Compare

FARN vs. AVCT, PRTC, HZD, VRP, and BTG

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? MarketBeat compares Faron Pharmaceuticals Oy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Faron Pharmaceuticals Oy include Avacta Group (AVCT), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Avacta Group (LON:AVCT) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Avacta Group's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Faron Pharmaceuticals Oy	Neutral

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 49.1% of Avacta Group shares are owned by insiders. Comparatively, 2.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.108, meaning that its stock price is 11% more volatile than the broader market.

Avacta Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Avacta Group is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,966.27	-£30.08M	-£9.66	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 34.42%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Avacta Group is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

Summary

Avacta Group beats Faron Pharmaceuticals Oy on 10 of the 13 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Faron Pharmaceuticals Oy (LON:FARN) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, PureTech Health had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
PureTech Health	Neutral

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 286.61%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Faron Pharmaceuticals Oy has higher earnings, but lower revenue than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
PureTech Health	£4.66M	68.65	-£91.86M	-£46.00	N/A

Faron Pharmaceuticals Oy has a beta of 1.108, suggesting that its share price is 11% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.811, suggesting that its share price is 19% less volatile than the broader market.

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 34.0% of PureTech Health shares are held by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 13.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 8 of the 14 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Faron Pharmaceuticals Oy	Neutral

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Summary

Faron Pharmaceuticals Oy beats Horizon Discovery Group plc (HZD.L) on 4 of the 7 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

In the previous week, Verona Pharma plc (VRP.L)'s average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
Faron Pharmaceuticals Oy	Neutral

Summary

Faron Pharmaceuticals Oy beats Verona Pharma plc (VRP.L) on 4 of the 6 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to BTG?

Faron Pharmaceuticals Oy (LON:FARN) and BTG (LON:BTG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

BTG has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
BTG	£159.40M	1.21	N/A	£6.00	20.00

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 19.7% of BTG shares are owned by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 19.7% of BTG shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BTG has a consensus target price of GBX 160, indicating a potential upside of 33.33%. Given BTG's stronger consensus rating and higher possible upside, analysts plainly believe BTG is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, BTG had 6 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 6 mentions for BTG and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 beat BTG's score of -0.22 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
BTG	Neutral

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
BTG	N/A	N/A	N/A

Summary

BTG beats Faron Pharmaceuticals Oy on 10 of the 12 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£84.10M	£381.57M	£6.65B	£2.88B
Dividend Yield	N/A	3.86%	2.68%	6.15%
P/E Ratio	-1.91	3.12	24.75	366.85
Price / Sales	N/A	6,861.77	529.30	86,444.11
Price / Cash	20.00	13.13	27.92	27.85
Price / Book	0.02	92.26	10.81	8.01
Net Income	-£60.23M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-4.10%	0.88%	0.72%	0.07%
1 Month Performance	0.36%	-0.66%	0.41%	0.93%
1 Year Performance	-79.55%	54.58%	29.34%	72.13%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 42.15 -3.1%	N/A	-79.5%	£84.10M	N/A	N/A	34	Gap Up
AVCT Avacta Group	N/A	GBX 70.78 +3.3%	GBX 99 +39.9%	+126.6%	£311.75M	£113K	N/A	120	Gap Up
PRTC PureTech Health	1.4918 of 5 stars	GBX 131.20 +2.8%	GBX 508 +287.2%	+1.7%	£310.60M	£4.66M	N/A	300	Positive News
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. AVCT, PRTC, HZD, VRP, and BTG

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. AVCT, PRTC, HZD, VRP, and BTG

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Does the media refer more to AVCT or FARN?

Do insiders & institutionals believe in AVCT or FARN?

Which has more volatility & risk, AVCT or FARN?

Which has stronger earnings & valuation, AVCT or FARN?

Do analysts prefer AVCT or FARN?

Is AVCT or FARN more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Does the media favor FARN or PRTC?

Do analysts rate FARN or PRTC?

Which has higher valuation & earnings, FARN or PRTC?

Which has more risk and volatility, FARN or PRTC?

Do insiders and institutionals have more ownership in FARN or PRTC?

Is FARN or PRTC more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Does the media prefer HZD or FARN?

Is HZD or FARN more profitable?

Do institutionals & insiders have more ownership in HZD or FARN?

Which has preferable earnings and valuation, HZD or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Is VRP or FARN more profitable?

Do insiders and institutionals have more ownership in VRP or FARN?

Which has better earnings and valuation, VRP or FARN?

Does the media prefer VRP or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Which has higher earnings & valuation, FARN or BTG?

Do institutionals and insiders believe in FARN or BTG?

Do analysts rate FARN or BTG?

Does the media favor FARN or BTG?

Is FARN or BTG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools